Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor.
Fifteen patients with progressive metastatic renal cell carcinoma were treated with granulocyte-macrophage colony-stimulating factor and intravenous infusions of activated autologous macrophages (AAMs). The latter were prepared from leukapheresis-separated mononuclear cells cultured in the presence of granulocyte-macrophage colony-stimulating factor, exposed to gamma interferon, and submitted to elutriation to separate AAMs. Three intravenous injections of AAMs were performed within a 2-week interval. This treatment cycle was repeated once or twice, in cases of tumor response or stabilization. Ninety-seven preparations containing a mean 3 x 10(9) AAMs were administered and usually well tolerated. One partial response, eight stabilizations and six progressions were observed. The median time to progression and median overall survival time after inclusion were 7 and 9 months, respectively. The cells injected did not accumulate substantially in tumor lesions, as shown by scintigraphic imaging of indium-111-labeled AAMs. Thus, combined granulocyte-macrophage colony-stimulating factor and AAM treatment was well tolerated and resulted in transitory stabilization (n = 8) or partial regression (n = 1) in 9 of 15 patients.
Lesimple
T
T
Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France.
Moisan
A
A
Guillé
F
F
Leberre
C
C
Audran
R
R
Drenou
B
B
Toujas
L
L
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D016207:Cytokines / Q000096:biosynthesis; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D007205:Indium Radioisotopes / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000637:transplantation*; D009362:Neoplasm Metastasis; D014182:Transplantation, Autologous
D000276:Adjuvants, Immunologic; D016207:Cytokines; D007205:Indium Radioisotopes; D016178:Granulocyte-Macrophage Colony-Stimulating Factor